Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors; it is characterized by muscle weakness and fatigue. Acetylcholinesterase inhibitors (e.g., pyridostigmine), corticosteroids (e.g., prednisone), and short- and long-term immunosuppressants (e.g., mycophenolate mofetil, azathioprine) are the most prescribed agents to manage the symptoms of MG. However, the MG pipeline is starting to bring therapies with unique mechanisms of action to the market, highlighted by the FDA’s approval of eculizumab (Alexion / AstraZeneca’s Soliris) in 2017, efgartigimod alfa (Argenx’s Vyvgart) in 2021, and ravulizumab (Alexion / AstraZeneca’s Ultomiris) in 2022. As the treatment landscape for MG continues to evolve, this report offers insight based on real-world claims data into prescribing trends for MG to help new players understand current treatment practices and to define the market niche for their emerging products.
Markets covered: United States
Key companies: Alexion, Argenx, AstraZeneca
Key drugs: Soliris, Ultomiris, Vyvgart, pyridostigmine, prednisone, azathioprine, mycophenolate mofetil, rituximab, intravenous immunoglobulin
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.